# A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

> **NCT06539338** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Kite, A Gilead Company** · enrollment: 10 (actual)

## Conditions studied

- Lymphomas Non-Hodgkin's B-Cell
- Precursor Cell Lymphoblastic Leukemia-Lymphoma

## Interventions

- **GENETIC:** INT2104

## Key facts

- **NCT ID:** NCT06539338
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-20
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06539338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06539338, "A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06539338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*